sorafenib has been researched along with pravastatin in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pravastatin) | Trials (pravastatin) | Recent Studies (post-2010) (pravastatin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 3,575 | 1,036 | 816 |
| Protein | Taxonomy | sorafenib (IC50) | pravastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.1452 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0056 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0056 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0254 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbier, E; Bouché, O; Bronowicki, JP; Debette-Gratien, M; Denis, J; Faroux, R; Jouve, JL; Khemissa Akouz, F; Lecomte, T; Legoux, JL; Manfredi, S; Nguyen Khac, E; Ollivier-Hourmand, I; Phelip, JM; Ramee, JF; Riachi, G; Seitz, JF; Vergniol, J; Villing, AL | 1 |
| Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL | 1 |
1 review(s) available for sorafenib and pravastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for sorafenib and pravastatin
| Article | Year |
|---|---|
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pravastatin; Prognosis; Progression-Free Survival; Quality of Life; Sorafenib | 2019 |
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |